Citi raised the firm’s price target on Summit Therapeutics (SMMT) to $40 from $35 and keeps a Buy rating on the shares. The firm has higher conviction in ivonescimab following the HARMONi-6 data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit announces ivonescimab, chemo showed improvement in primary endpoint
- Summit Therapeutics PLC (SMMT) Q3 Earnings Cheat Sheet
- Summit Therapeutics announces expansion of Phase III program of ivonescimab
- Citizens JMP healthcare analysts hold an analyst/industry conference call
- Positive Outlook for Summit Therapeutics Driven by Anticipated HARMONi-6 Trial Success